Toggle Main Menu Toggle Search

Open Access padlockePrints

In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: Implications for the control of graft-versus-host disease

Lookup NU author(s): Professor Matthew CollinORCiD, Dr Xiao WangORCiD, Professor Anne Dickinson


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Graft-versus-host disease (GvHD), a life-threatening complication of bone marrow transplantation, is initiated by donor T cells reacting to recipient dendritic cells (DC). GvHD can be controlled by attenuating donor T cells, but few strategies exist to target DC, particularly resident tissue DC, despite recent evidence of their importance. In this report, CMRF-44, a mouse monoclonal IgM reactive to human DC, is tested against human Langerhans cells (LC) in vitro. CMRF-44 antigen is expressed at low level on fresh LC but is up-regulated 40-60-fold during migration. CMRF-44 and complement kill more than 97% of migratory LC in vitro and inhibit allostimulation by LC up to 95%. In comparison, alemtuzumab, which binds CD52, reacts weakly with primary LC and fails to induce significant lysis with complement (less than 5%). These results highlight the potential of new therapeutic antibodies active against tissue DC to control graft-versus-host reactions. Copyright © 2005 by Lippincott Williams & Wilkins.

Publication metadata

Author(s): Collin MP, Munster D, Clark G, Wang X-N, Dickinson AM, Hart DN

Publication type: Article

Publication status: Published

Journal: Transplantation

Year: 2005

Volume: 79

Issue: 6

Pages: 722-725

ISSN (print): 0041-1337

ISSN (electronic): 1534-6080

Publisher: Lippincott Williams & Wilkins


DOI: 10.1097/01.TP.0000149321.86104.C4

PubMed id: 15785380


Altmetrics provided by Altmetric